Literature DB >> 25728733

Effects of acute kidney injury and chronic kidney disease on long-term mortality after coronary artery bypass grafting.

Seung Seok Han1, Nara Shin1, Seon Ha Baek2, Shin Young Ahn2, Dong Ki Kim1, Sejoong Kim2, Ho Jun Chin2, Dong-Wan Chae2, Ki Young Na3.   

Abstract

BACKGROUND: Both acute kidney injury (AKI) and chronic kidney disease (CKD) are important issues in patients undergoing coronary artery bypass grafting (CABG), particularly with regard to mortality. However, their synergistic or discrete effects on long-term mortality remain unresolved.
METHODS: A total of 1,899 patients undergoing CABG were retrospectively analyzed. The adjusted hazard ratios for all-cause mortality were calculated after stratifying the timeframes. To evaluate the synergistic effects between AKI and CKD, the relative excess risk due to interaction was applied.
RESULTS: The presence of AKI, CKD, or both increased the hazard ratios for mortality, compared with the absence of both: AKI alone, 1.84 (1.464-2.319); CKD alone, 2.46 (1.735-3.478); and AKI and CKD together, 3.21 (2.301-4.488). However, the relationships with mortality were different between AKI and CKD, according to the timeframes: AKI primarily affected early mortality, particularly within 3 years, whereas CKD had a relatively constant effect on both the early and late periods. When the parameters from the relative excess risk due to interaction were obtained, there was a synergistic additive effect on early mortality between AKI and CKD.
CONCLUSIONS: The relationships with mortality after CABG were different between AKI and CKD. However, their effects were not exclusive but synergistic.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 25728733     DOI: 10.1016/j.ahj.2014.12.019

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  7 in total

1.  Serum alpha 1-antitrypsin predicts severe acute kidney injury after cardiac surgery.

Authors:  Songlin Du; Jianwei Tian; Zhiwen Xiao; Zhiwen Luo; Tong Lin; Shaoyi Zheng; Jun Ai
Journal:  J Thorac Dis       Date:  2019-12       Impact factor: 2.895

2.  Improving the Prediction of Cardiac Surgery-Associated Acute Kidney Injury.

Authors:  Jordan Crosina; Jordyn Lerner; Julie Ho; Navdeep Tangri; Paul Komenda; Brett Hiebert; Nora Choi; Rakesh C Arora; Claudio Rigatto
Journal:  Kidney Int Rep       Date:  2016-10-21

3.  Development of model to predict end-stage renal disease after coronary artery bypass grafting: The ACHE score.

Authors:  Yeonhee Lee; Jiwon Park; Myoung-Jin Jang; Hong Ran Moon; Dong Ki Kim; Kook-Hwan Oh; Kwon Wook Joo; Chun Soo Lim; Yon Su Kim; Ki Young Na; Seung Seok Han
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

4.  Novel Plasma Biomarker-Based Model for Predicting Acute Kidney Injury After Cardiac Surgery: A Case Control Study.

Authors:  Yichi Zhang; Haige Zhao; Qun Su; Cuili Wang; Hongjun Chen; Lingling Shen; Liang Ma; Tingting Zhu; Wenqing Chen; Hong Jiang; Jianghua Chen
Journal:  Front Med (Lausanne)       Date:  2022-01-14

5.  Hyperchloremia is associated with poor renal outcome after coronary artery bypass grafting.

Authors:  Jae Shin Choi; Donghwan Yun; Dong Ki Kim; Kook-Hwan Oh; Kwon Wook Joo; Yon Su Kim; Ki Young Na; Seung Seok Han
Journal:  BMC Nephrol       Date:  2021-10-18       Impact factor: 2.388

6.  The neutrophil to lymphocyte ratio and serum albumin as predictors of acute kidney injury after coronary artery bypass grafting.

Authors:  Masashi Ishikawa; Masae Iwasaki; Dai Namizato; Makiko Yamamoto; Tomonori Morita; Yosuke Ishii; Atsuhiro Sakamoto
Journal:  Sci Rep       Date:  2022-09-14       Impact factor: 4.996

7.  Short-term outcomes of on- vs off-pump coronary artery bypass grafting in patients with left ventricular dysfunction: a systematic review and meta-analysis.

Authors:  Zhiyuan Guan; Xiaoqing Guan; Kaiyun Gu; Xuanqi Lin; Jin Lin; Wenjun Zhou; Ming Xu; Fen Wan; Zhe Zhang; Chunli Song
Journal:  J Cardiothorac Surg       Date:  2020-05-11       Impact factor: 1.637

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.